- ADCT Dashboard
-
Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
ADC Therapeutics (ADCT) Financial statements
Company Profile
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|
Total Revenue | |||||
Cost of Revenue | |||||
Gross Profit | |||||
Gross Profit Margin (%) | |||||
R&D Expense | |||||
SG&A Expense | |||||
Total Operating Expenses | |||||
Operating Income or Loss | |||||
Operating Margin (%) | |||||
Interest Expense | |||||
Total Other Income/Expenses | |||||
Income Before Tax | |||||
Income Tax Expense | |||||
Income from Continuing Ops. | |||||
Net Income | |||||
Net Profit Margin (%) | |||||
Net Income Available to Common Shareholders | |||||
Basic EPS | |||||
Diluted EPS | |||||
Basic Average Shares | |||||
Diluted Average Shares |
Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|---|---|---|
Total Revenue | ||||||||
Cost of Revenue | ||||||||
Gross Profit | ||||||||
Gross Profit Margin (%) | ||||||||
R&D Expense | ||||||||
SG&A Expense | ||||||||
Total Operating Expenses | ||||||||
Operating Income or Loss | ||||||||
Operating Margin (%) | ||||||||
Interest Expense | ||||||||
Total Other Income/Expenses | ||||||||
Income Before Tax | ||||||||
Income Tax Expense | ||||||||
Income from Continuing Ops. | ||||||||
Net Income | ||||||||
Net Profit Margin (%) | ||||||||
Net Income Available to Common Shareholders | ||||||||
Basic EPS | ||||||||
Diluted EPS | ||||||||
Basic Average Shares | ||||||||
Diluted Average Shares |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|
Current Assets | |||||
Cash & Cash Equivalents | |||||
Marketable Securities | |||||
Receivables | |||||
Inventories | |||||
Other Current Assets | |||||
Total Current Assets | |||||
Non-Current Assets | |||||
Marketable Securities | |||||
PPE Net | |||||
Intangibles inc. Goodwill | |||||
Other Non-Current Assets | |||||
Total Non-Current Assets | |||||
Total Assets | |||||
Current Liabilities | |||||
Accounts Payable | |||||
Deferred Revenues | |||||
Debt, Current | |||||
Accrued Liabilities | |||||
Other Current Liabilities | |||||
Total Current Liabilities | |||||
Non-Current Liabilities | |||||
Deferred Revenues | |||||
Debt, Non-Current | |||||
Other Non-Current Liabilities | |||||
Total Non-Current Liabilities | |||||
Total Liabilities | |||||
Shareholders' Equity | |||||
Common Stock | |||||
Additional Paid-In Capital | |||||
Retained Earnings | |||||
Other Shareholders' Equity | |||||
Total Shareholders' Equity | |||||
Total Liabilities & Shareholders' Equity |
Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|---|---|---|
Current Assets | ||||||||
Cash & Cash Equivalents | ||||||||
Marketable Securities | ||||||||
Receivables | ||||||||
Inventories | ||||||||
Other Current Assets | ||||||||
Total Current Assets | ||||||||
Non-Current Assets | ||||||||
Marketable Securities | ||||||||
PPE Net | ||||||||
Intangibles inc. Goodwill | ||||||||
Other Non-Current Assets | ||||||||
Total Non-Current Assets | ||||||||
Total Assets | ||||||||
Current Liabilities | ||||||||
Accounts Payable | ||||||||
Deferred Revenues | ||||||||
Debt, Current | ||||||||
Accrued Liabilities | ||||||||
Other Current Liabilities | ||||||||
Total Current Liabilities | ||||||||
Non-Current Liabilities | ||||||||
Deferred Revenues | ||||||||
Debt, Non-Current | ||||||||
Other Non-Current Liabilities | ||||||||
Total Non-Current Liabilities | ||||||||
Total Liabilities | ||||||||
Shareholders' Equity | ||||||||
Common Stock | ||||||||
Additional Paid-In Capital | ||||||||
Retained Earnings | ||||||||
Other Shareholders' Equity | ||||||||
Total Shareholders' Equity | ||||||||
Total Liabilities & Shareholders' Equity |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|
Cash Flows from Operating Activities | |||||
Net Income | |||||
Depreciation & Amortization | |||||
Deferred Income Taxes | |||||
Stock Based Compensation | |||||
Accounts Receivable | |||||
Inventory | |||||
Accounts Payable | |||||
Deferred Revenue | |||||
Other Non-Cash | |||||
Operating Cash Flow | |||||
Cash Flows from Investing Activities | |||||
PPE Investments | |||||
Net Acquisitions | |||||
Purchase of Investments | |||||
Sale of Investments | |||||
Other Investing Activity | |||||
Investing Cash Flow | |||||
Cash Flows from Financing Activities | |||||
Debt Issued | |||||
Proceeds from Debt Repayment | |||||
Debt Repayment | |||||
Proceeds from Sale of Equity | |||||
Equity Repurchased | |||||
Dividend Paid | |||||
Other Financing Activity | |||||
Financing Cash Flow | |||||
Cash Position | |||||
Beginning Cash Position | |||||
End Cash Position | |||||
Change in Cash | |||||
Free Cash Flow | |||||
Operating Cash Flow | |||||
Capital Expenditure | |||||
Free Cash Flow |
Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | ||
---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | ||||||||
Net Income | ||||||||
Depreciation & Amortization | ||||||||
Deferred Income Taxes | ||||||||
Stock Based Compensation | ||||||||
Accounts Receivable | ||||||||
Inventory | ||||||||
Accounts Payable | ||||||||
Deferred Revenue | ||||||||
Other Non-Cash | ||||||||
Operating Cash Flow | ||||||||
Cash Flows from Investing Activities | ||||||||
PPE Investments | ||||||||
Net Acquisitions | ||||||||
Purchase of Investments | ||||||||
Sale of Investments | ||||||||
Other Investing Activity | ||||||||
Investing Cash Flow | ||||||||
Cash Flows from Financing Activities | ||||||||
Debt Issued | ||||||||
Proceeds from Debt Repayment | ||||||||
Debt Repayment | ||||||||
Proceeds from Sale of Equity | ||||||||
Equity Repurchased | ||||||||
Dividend Paid | ||||||||
Other Financing Activity | ||||||||
Financing Cash Flow | ||||||||
Cash Position | ||||||||
Beginning Cash Position | ||||||||
End Cash Position | ||||||||
Change in Cash | ||||||||
Free Cash Flow | ||||||||
Operating Cash Flow | ||||||||
Capital Expenditure | ||||||||
Free Cash Flow |